AI-driven intelligence platform Sorcero has secured $42.5m in a Series B funding round to expedite its global growth in the medical device, medical affairs, safety and scientific communications sectors.
The funding will also support further development of the AI platform to facilitate a medical-insights-driven engagement model and help address the life sciences industry’s need to promote the adoption of new therapies.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
NewSpring Growth spearheaded the funding round, which also saw participation from Leawood Venture Capital and Blu Ventures.
This latest round brings Sorcero’s total funding to $59m.
The platform is used by pharmaceutical firms to identify actionable findings from medical data and enable evidence-based, tailored engagement with healthcare professionals.
Sorcero is claimed to have helped users increase productivity in the generation of scientific evidence by as much as 92%, expedite the generation of insights by up to 72%, and deliver manuscripts, evidence, and value dossiers two to five months quicker compared to manual processes.
The Sorcero Intelligence Platform comprises Sorcero Medical, Sorcero Medtech, Sorcero Safety, and Sorcero SciComms.
It is said to integrate several sources to provide a broad view of more than 40 million healthcare professionals and 100 million published scientists globally.
The platform continuously tracks product performance and safety, providing up-to-date insights for those working in precision medicine.
Sorcero co-founder and CEO Dipanwita Das said: “Our vision is to create a unified intelligence platform for the precision medicine era. We’re pioneering a new evidence-based medical affairs model where science, personalised for physicians, drives engagement and product adoption.
“This puts doctors’ evidence needs at the centre and helps life sciences generate real-world insights radically faster, identify patients in need of specific treatments, and continually improve patient outcomes to drive healthcare provider adoption.”
